Randomized Trialhigh evidence
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
The lancet. Diabetes & endocrinology·June 7, 2026·PMID 42251860
Why it mattersCagriSema combines amylin and GLP-1 agonism, offering robust glycemic and weight control in early diabetes. This dual mechanism may address unmet needs in metabolic therapeutics, potentially improving outcomes beyond current GLP-1 monotherapy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled